A087010 Stock Overview
Engages in the development of peptide-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Peptron, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩114,000.00 |
| 52 Week High | ₩132,000.00 |
| 52 Week Low | ₩21,100.00 |
| Beta | 0.76 |
| 11 Month Change | 18.63% |
| 3 Month Change | 112.69% |
| 1 Year Change | 257.93% |
| 33 Year Change | 1,006.80% |
| 5 Year Change | 744.44% |
| Change since IPO | 448.08% |
Recent News & Updates
Peptron (KOSDAQ:087010) Is Carrying A Fair Bit Of Debt
Jun 10
Does Peptron (KOSDAQ:087010) Have A Healthy Balance Sheet?
Feb 26Shareholder Returns
| A087010 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -4.7% | -9.0% | -2.8% |
| 1Y | 257.9% | 33.1% | -3.4% |
Return vs Industry: A087010 exceeded the KR Life Sciences industry which returned 33.1% over the past year.
Return vs Market: A087010 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A087010 volatility | |
|---|---|
| A087010 Average Weekly Movement | 16.1% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A087010's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A087010's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Ho-Il Choi | www.peptron.co.kr |
Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence.
Peptron, Inc. Fundamentals Summary
| A087010 fundamental statistics | |
|---|---|
| Market cap | ₩2.35t |
| Earnings (TTM) | -₩19.62b |
| Revenue (TTM) | ₩2.50b |
941.1x
P/S Ratio-120.0x
P/E RatioIs A087010 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A087010 income statement (TTM) | |
|---|---|
| Revenue | ₩2.50b |
| Cost of Revenue | ₩1.84b |
| Gross Profit | ₩661.32m |
| Other Expenses | ₩20.28b |
| Earnings | -₩19.62b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -949.87 |
| Gross Margin | 26.43% |
| Net Profit Margin | -784.13% |
| Debt/Equity Ratio | 35.8% |
How did A087010 perform over the long term?
See historical performance and comparison